Open AccessS126: GEMTUZUMAB‐BASED INDUCTION CHEMOTHERAPY COMBINED WITH MIDOSTAURIN FOR FLT3 MUTATED AML. RESULTS FROM THE NCRI AML19 “MIDOTARG” PILOT TRIAL
Author(s) -
Russell N.,
WilhelmBenartzi C.,
Othman J.,
Dillon R.,
Potter N.,
Jovanovic J.,
Gilkes A.,
Batten L. M.,
Canham J.,
Hinson E. L.,
Kottaridis P.,
Cavenagh J.,
Arnold C.,
Dennis M.,
Knapper S.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000843396.14484.b9
Subject(s) - midostaurin , gemtuzumab ozogamicin , medicine , induction chemotherapy , daunorubicin , oncology , cytarabine , chemotherapy , leukemia , cd33 , stem cell , biology , cd34 , genetics